Two Sigma Investments’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Two Sigma Investments’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-88,753	Closed	-$803K	–	2529
2013 Q4	$803K	Buy	+88,753	New	+$641K	﹤0.01%	1432
2013 Q3	–	Sell	-24,324	Closed	-$166K	–	2350
2013 Q2	$166K	Buy	+24,324	New	+$169K	﹤0.01%	1815

Other funds holding CADX

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Two Sigma Investments's CADX Position: Q1 2014 in Review

Two Sigma Investments sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 88,753 shares — an estimated $803K sold.

Two Sigma Investments first reported a position in CADX in Q2 2013 and held it in 2 quarters. The position peaked at $803K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

Two Sigma Investments reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
Two Sigma Investments sold 88,753 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $803K.
Two Sigma Investments first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 2 quarters.
Two Sigma Investments's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $803K in Q4 2013.
3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Two Sigma Investments's 13F filing for Q1 2014, filed 15 May 2014.